Pacific Biosciences of Ca... (PACB)
Pacific Biosciences of California Statistics
Share Statistics
Pacific Biosciences of California has 273.86M shares outstanding. The number of shares has increased by 2.21% in one year.
| Shares Outstanding | 273.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 241.84M |
| Failed to Deliver (FTD) Shares | 119.93K |
| FTD / Avg. Volume | 1.13% |
Short Selling Information
The latest short interest is 60.54M, so 22.11% of the outstanding shares have been sold short.
| Short Interest | 60.54M |
| Short % of Shares Out | 22.11% |
| Short % of Float | 25.03% |
| Short Ratio (days to cover) | 6.95 |
Valuation Ratios
The PE ratio is -8.11 and the forward PE ratio is -2.5.
| PE Ratio | -8.11 |
| Forward PE | -2.5 |
| PS Ratio | 12.41 |
| Forward PS | 1.8 |
| PB Ratio | 3.55 |
| P/FCF Ratio | -9.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Pacific Biosciences of California Inc. has an Enterprise Value (EV) of 3.24B.
| EV / Earnings | -10.57 |
| EV / Sales | 16.17 |
| EV / EBITDA | -11.69 |
| EV / EBIT | -9.69 |
| EV / FCF | -12.1 |
Financial Position
The company has a current ratio of 7.81, with a Debt / Equity ratio of 1.33.
| Current Ratio | 7.81 |
| Quick Ratio | 7.21 |
| Debt / Equity | 1.33 |
| Total Debt / Capitalization | 57.11 |
| Cash Flow / Debt | -0.28 |
| Interest Coverage | -23.32 |
Financial Efficiency
Return on equity (ROE) is -0.44% and return on capital (ROIC) is -19.72%.
| Return on Equity (ROE) | -0.44% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -19.72% |
| Revenue Per Employee | 251.91K |
| Profits Per Employee | -385.35K |
| Employee Count | 796 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 2.61 |
Taxes
| Income Tax | -11.42M |
| Effective Tax Rate | 0.04 |
Stock Price Statistics
The stock price has increased by -77.35% in the last 52 weeks. The beta is 2.01, so Pacific Biosciences of California 's price volatility has been higher than the market average.
| Beta | 2.01 |
| 52-Week Price Change | -77.35% |
| 50-Day Moving Average | 1.88 |
| 200-Day Moving Average | 1.8 |
| Relative Strength Index (RSI) | 39.54 |
| Average Volume (20 Days) | 10.61M |
Income Statement
In the last 12 months, Pacific Biosciences of California had revenue of 200.52M and earned -306.74M in profits. Earnings per share was -1.21.
| Revenue | 200.52M |
| Gross Profit | 52.78M |
| Operating Income | -334.47M |
| Net Income | -306.74M |
| EBITDA | -277.28M |
| EBIT | -334.47M |
| Earnings Per Share (EPS) | -1.21 |
Balance Sheet
The company has 179.91M in cash and 933.93M in debt, giving a net cash position of -754.02M.
| Cash & Cash Equivalents | 179.91M |
| Total Debt | 933.93M |
| Net Cash | -754.02M |
| Retained Earnings | -1.84B |
| Total Assets | 1.45B |
| Working Capital | 524.24M |
Cash Flow
In the last 12 months, operating cash flow was -259.17M and capital expenditures -8.84M, giving a free cash flow of -268.02M.
| Operating Cash Flow | -259.17M |
| Capital Expenditures | -8.84M |
| Free Cash Flow | -268.02M |
| FCF Per Share | -1.06 |
Margins
Gross margin is 26.32%, with operating and profit margins of -166.8% and -152.97%.
| Gross Margin | 26.32% |
| Operating Margin | -166.8% |
| Pretax Margin | -158.67% |
| Profit Margin | -152.97% |
| EBITDA Margin | -138.28% |
| EBIT Margin | -166.8% |
| FCF Margin | -133.66% |
Dividends & Yields
PACB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -76.1% |
| FCF Yield | -61.55% |
Analyst Forecast
The average price target for PACB is $2.5, which is 57.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.5 |
| Price Target Difference | 57.2% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | -2.11 |
| Piotroski F-Score | 2 |